Can Spyre Therapeutics (SYRE) Climb 158.85% to Reach the Level Wall Street Analysts Expect?

Core Viewpoint - Spyre Therapeutics (SYRE) has shown a 0.9% increase in share price over the past four weeks, closing at $22.65, with analysts projecting a potential upside of 158.9$58.63 [1][12]. Price Targets - The average price target consists of eight estimates ranging from a low of $40 to a high of$71, with a standard deviation of $12.36, indicating variability among analysts [2]. - The lowest estimate suggests a 76.6% increase from the current price, while the highest estimate indicates a 213.5% upside [2]. Analyst Sentiment - There is strong agreement among analysts regarding SYRE's ability to exceed previous earnings predictions, which supports the expectation of a stock price increase [4][9]. - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 2%, with one estimate increasing and no negative revisions [10]. Zacks Rank - SYRE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting a strong potential for upside in the near term [11].